News coverage about Sophiris Bio (NASDAQ:SPHS) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sophiris Bio earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.8107482970157 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Analyzing Sophiris Bio (SPHS) and The Competition (americanbankingnews.com)
- Sophiris Bio’s (SPHS) Buy Rating Reaffirmed at HC Wainwright (americanbankingnews.com)
- Sophiris Bio Reports Third Quarter Financial Results and Key Corporate Highlights – Markets Insider (markets.businessinsider.com)
A number of research firms recently issued reports on SPHS. Maxim Group set a $6.00 price target on shares of Sophiris Bio and gave the company a “buy” rating in a research note on Monday, October 2nd. HC Wainwright set a $6.00 price target on shares of Sophiris Bio and gave the company a “buy” rating in a research note on Friday, August 11th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Sophiris Bio currently has an average rating of “Buy” and an average price target of $6.25.
Sophiris Bio (NASDAQ:SPHS) traded down $0.12 during trading on Tuesday, reaching $2.06. 182,600 shares of the company were exchanged, compared to its average volume of 287,178. Sophiris Bio has a 1 year low of $1.80 and a 1 year high of $3.24. The company has a debt-to-equity ratio of 0.60, a quick ratio of 13.37 and a current ratio of 13.37.
ILLEGAL ACTIVITY NOTICE: This piece was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://ledgergazette.com/2017/11/14/sophiris-bio-sphs-given-media-sentiment-rating-of-0-17.html.
Sophiris Bio Company Profile
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.